Pharmaceutical giant Eli Lilly (LLY) has increased its quarterly dividend payment for an 11th consecutive year as the company benefits from blockbuster sales of its weight-loss drug Zepbound.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Eli Lilly just declared that it will pay a dividend for this year’s third quarter of $1.50 a share. That’s up slightly from a previous quarterly distribution of $1.49. The Q3 dividend is payable on Sept. 10 to shareholders of record at market close on August 15.
Eli Lilly has steadily increased its dividend every year since 2014 at an average annual increase of 15%. The company’s payout ratio now stands at 43.74%, which means that a little less than 44% of the company’s profits are paid to shareholders in the form of dividends.
Low Distribution Rate
While Eli Lilly’s annual dividend, or the the total amount of dividends paid to shareholders in a year, is $6, the company is known for having a low distribution rate. Currently, LLY stock has a dividend yield of 0.77%, which is below the average of 1.27% among companies listed on the benchmark S&P 500 index.
Analysts say the low dividend payout ratio is due to the fact that Eli Lilly is investing heavily in its future growth, particularly as it relates to the manufacturing of its weight-loss medications. At the same time, the low distribution means that Eli Lilly’s dividend is safe and sustainable, and that the pharmaceutical company can likely keep raising it in coming years. LLY stock is up 3% this year.
Is LLY Stock a Buy?
The stock of Eli Lilly has a consensus Strong Buy recommendation among 19 Wall Street analysts. That rating is based on 16 Buy, two Hold, and one Sell recommendations issued in the last 12 months. The average LLY price target of $999.57 implies 29.71% upside from current levels.
